Glutamic acid decarboxylase (GAD) based delivery system
The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.
1. A method for treating epilepsy in a subject comprising:
identifying one or more regions in a hippocampus that require modification;
delivering an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding a glutamic acid decarboxylase (GAD) directly to the hippocampus; and
expressing the GAD in the hippocampus to treat or reduce epilepsy.
2. The method of claim 1 , wherein the adeno-associated viral vector is selected from the group consisting of AAV-1 AAV-2, AAV-3, AAV-4, AAV-5 and AAV-7.
3. The method of claim 1 , wherein the adeno-associated viral vector is AAV-2.
4. The method of claim 1 , wherein the glutamic acid decarboxylase (GAD) is glutamic acid decarboxylase 65 (GAD 65 ).
5. The method of claim 1 , wherein the glutamic acid decarboxylase (GAD) is glutamic acid decarboxylase 67 (GAD 67 ).
6. The method of claim 1 , wherein the vector is delivered using stereotaxic delivery.